WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $96,586 | $64,654 | $43,169 | $118,107 |
| - Cash | $8,439 | $8,279 | $9,154 | $9,670 |
| + Debt | $5,107 | $4,940 | $4,567 | $4,561 |
| Enterprise Value | $93,254 | $61,314 | $38,583 | $112,999 |
| Revenue | $9,953 | $10,101 | $8,574 | $8,542 |
| % Growth | -1.5% | 17.8% | 0.4% | – |
| Gross Profit | $4,253 | $4,301 | $3,350 | $3,267 |
| % Margin | 42.7% | 42.6% | 39.1% | 38.2% |
| EBITDA | $3,449 | $3,956 | $2,473 | $2,128 |
| % Margin | 34.7% | 39.2% | 28.8% | 24.9% |
| Net Income | $2,339 | $1,857 | $1,499 | $1,133 |
| % Margin | 23.5% | 18.4% | 17.5% | 13.3% |
| EPS Diluted | 0.55 | 0.43 | 0.35 | 0.26 |
| % Growth | 27.9% | 22.9% | 34.6% | – |
| Operating Cash Flow | $1,807 | $3,915 | $1,302 | $2,334 |
| Capital Expenditures | -$1,900 | -$2,062 | -$1,867 | -$2,115 |
| Free Cash Flow | -$94 | $1,853 | -$565 | $219 |